Form 4: Cingulate Director John A. Roberts Granted 15,000 Stock Options

Cingulate Inc. Director John A. Roberts was granted 15,000 stock options with an exercise price of $4.14, as disclosed in a recent SEC Form 4 filing.

Summary

• John A. Roberts, a Director of Cingulate Inc. (CING), reported the acquisition of 15,000 derivative securities in the form of stock options.
• The transaction date for the grant was June 20, 2025.
• Each stock option has an exercise price of $4.14.
• The options are exercisable into 15,000 shares of Cingulate Inc. Common Stock.
• The expiration date for these stock options is June 20, 2035.
• The options will vest on the earlier of (i) the one-year anniversary of the grant date (June 20, 2026) or (ii) the date of the Cingulate Inc. 2026 annual meeting of stockholders.
• Following this transaction, John A. Roberts directly beneficially owns 15,000 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as the grant of stock options aligns the director's interests with shareholders, which is generally viewed favorably. However, it is a routine compensation event and not indicative of significant new developments.

Positives

• The grant of stock options to a director aligns their interests with those of shareholders, as the options gain value if the company's stock price increases.
• This is a standard form of compensation for directors, indicating continuity in corporate governance practices.

Risks

• The value of the stock options is subject to market fluctuations and the future performance of Cingulate Inc.'s common stock.
• If the stock price does not exceed the exercise price of $4.14, the options may expire worthless.

Future Outlook

The stock options are subject to a vesting schedule, becoming exercisable on the earlier of the one-year anniversary of the grant date (June 20, 2026) or the date of the Cingulate Inc. 2026 annual meeting of stockholders, indicating a future milestone for the director's equity ownership.

Industry Context

The granting of stock options to directors is a common practice across various industries, including the pharmaceutical and biotechnology sectors where Cingulate Inc. operates. It serves as a key component of executive and director compensation packages, aiming to incentivize long-term performance and align leadership interests with shareholder value.

Comparison to Industry Standards

• The grant of stock options to a director is a standard compensation mechanism widely adopted by publicly traded companies across various sectors, including biotech and pharmaceuticals.
• The exercise price of $4.14 per share is typical for options granted at the money, meaning the exercise price is equal to the stock's fair market value on the grant date.
• A 10-year expiration period (until June 20, 2035) is a common duration for employee and director stock options, providing a long-term incentive horizon.
• The vesting schedule, tied to either a one-year anniversary or the next annual meeting, is also a standard approach to ensure continued service and commitment from the director.

Related Party Transactions

• The grant of stock options to John A. Roberts, a Director of Cingulate Inc., constitutes a related party transaction as it involves compensation from the company to an insider. This is a standard and disclosed form of compensation.

Stakeholder Impact

• Shareholders: The grant of options can align the director's financial interests with shareholder value creation, as the options' value increases with the company's stock price.
• Employees: No direct impact on general employees is indicated by this filing.

Next Steps

• The stock options will vest on the earlier of June 20, 2026, or the date of the Cingulate Inc. 2026 annual meeting of stockholders, at which point they will become exercisable.

Key Dates

Keywords

Cingulate Inc., CING, Stock Options, Form 4, Insider Trading, Director Compensation, Equity Grant, Beneficial Ownership, SEC Filing